Design and manufacturing of high-quality recombinant proteins and enzymes.

For novel drug development.

Who are we?

KACTUS is a biotech company that specializes in providing high-purity, high-activity, recombinant protein and enzyme products for a range of fields including antibody drug discovery, immunotherapy, gene editing, and mRNA therapeutics.

What do we offer?

Catalog Products

Our catalog selection of 2500+ ready-made recombinant proteins includes various targets, species, tags, and labels. We carefully select our catalog based on product quality and unmet needs in the market.

Custom Services

The drug development market is ever-changing. If you don't see what you're looking for on our site, contact us to set up a custom project. Our team is dedicated to providing unparalleled quality and customer service.

Why are we here?

Our Mission

Provide first-to-market recombinant protein and enzymes to accelerate novel biopharma and diagnostic breakthroughs.

Our Differentiators

Design Expertise

Our expertise in protein design and enzymatic studies, along with our SAMS™ platform, will help you create a protein configuration that will be functional for your application while also optimizing purity & yield.

Tailored Expression System

After generating 3D models of your protein/enzyme, we test the configurations in various expression systems to optimize protein folding, maximize bioactivity, and enhance stability.

Quality Bulk Supply

We'll take your protein configuration from bench to large-scale production. Our quality control systems ensure batch-to-batch consistency and our facilities are prepared for consistent high-quantity production.

How did we get here?

March 2018


Established in 2018, KACTUS embarked on its journey with a resolute mission: to deliver innovative solutions to the realm of recombinant proteins, squarely addressing the unmet demands of researchers and the challenges posed by intricate protein expression.

July 2018

First company to express Claudin 18.2

Our esteemed scientific team achieved a remarkable breakthrough by becoming the first to successfully express the intricate multi-transmembrane protein Claudin 18.2. This achievement showcased the robust capabilities of our protein engineering capabilities.


SAMS Technology Platform

Having diligently pursued the recombinant expression of numerous proteins including MHCs and transmembrane proteins, our endeavors culminated in the conceptualization of our pioneering protein technology platform, aptly named Structure-Aided Multiplex Screening (SAMS).


Established GMP Enzyme Enterprise

In a significant stride forward, our transformation into a cGMP enzyme manufacturing facility in 2021 underscored our substantial commitment to commercialization solutions, enabling us to provide an extensive range of GMP-Grade mRNA and gene editing enzymes.


Onsite GMP Auditing & DMF Submissions

We achieved a significant milestone by passing onsite audits for our GMP-compliant facilities by esteemed clients in the gene editing and mRNA vaccine sectors. In alignment with our commitment to regulatory adherence and product quality, we took a proactive step by filing Drug Master Files (DMF) for our key GMP enzyme products. This initiative also underscored our unwavering focus on maintaining the highest standards of quality assurance.

February 2022

Making Products Accessible

In our quest to enhance accessibility to our products, we emphasized a global operational footprint, with international distributors, ready-to-ship products, and fast shipping speeds. Quality customer service is at the forefront of our logistics operations.

December 2022

GMP Enzyme Approved for Clinical Trial

Our GMP-Grade CRISPR Cas9 Enzyme was not only approved for use in Reforgene Medicine's Clinical Trial to treat beta-thalassemia but also stands as a testament to the authenticity and credibility of our state-of-the-art production facilities and comprehensive regulatory support.


Fueled by Purpose

Today, our solutions have expanded to include 2500+ recombinant proteins, 25+ GMP enzymes, and custom protein expression. We continue to launch new products and services to facilitate novel drug development, focusing on current challenges in R&D and commercialization.

Advanced Protein Engineering Platform

Our products are developed using our proprietary protein engineering platform, SAMS™. 3D protein structures are optimized using advanced bioinformatics, structural analysis, and 3D modeling. Multiple protein constructs are tested in various expression conditions to optimize activity, yield, and configuration. With this platform we have produced difficult-to-express targets such as CCR8 and Claudin 18.2 We've also developed VLP-displayed antigens, MHC complexes, AAV ELISA kits, DNA Amplification enzymes, Laminin 521, and GMP-Grade mRNA and gene editing enzymes.

Our Values


We strive to be a world-class biotechnology company, serving our global biopharma and diagnostics customers.


We value direct and open communication. We are problem-solvers and are responsive to constructive criticism.


We work together as a team toward our common goal. We contribute to the team, and we lean on the team for support


Problems are our fuel for improvement. We value ambitious and independent people with a strong desire for success, self-development, and even material returns.


We do not shy away from technological setbacks. We embrace novel design demands and first-to-market products.